Global Glucagon Like Peptide-1 (GLP-1) Agonists Competitive Landscape Professional Research Report 2024

Research Summary

Glucagon-like peptide-1 (GLP-1) agonists are a class of medications used in the treatment of type 2 diabetes. GLP-1 is a naturally occurring hormone that stimulates insulin secretion and inhibits glucagon release, contributing to blood sugar regulation. GLP-1 agonists are synthetic compounds designed to mimic the effects of this hormone. When administered as injectable medications, they enhance insulin production in response to elevated blood sugar levels, suppress glucagon secretion, slow down gastric emptying, and promote a feeling of fullness, which can aid in weight management. By targeting multiple aspects of glucose metabolism, GLP-1 agonists help lower blood sugar levels in individuals with type 2 diabetes. Additionally, these medications are associated with a lower risk of hypoglycemia compared to some other diabetes medications. Common examples of GLP-1 agonists include exenatide, liraglutide, and dulaglutide. They are often used as part of a comprehensive treatment plan that includes lifestyle modifications and other antidiabetic medications.

According to DIResearch's in-depth investigation and research, the global Glucagon Like Peptide-1 (GLP-1) Agonists market size will reach US$ XX Million in 2024, and is expected to reach US$ XX Million in 2030, with a CAGR of XX% (2025-2030). Among them, the China market has changed rapidly in the past few years. The market size in 2024 will be US$ XX Million, accounting for approximately XX% of the world. It is expected to reach US$ XX Million in 2030, and the global share will reach XX%.

The major global manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists include Novo Nordisk, AstraZeneca, Eli Lily, GSK, Sanofi, Amylin, Bristol-Myers Squibb etc. The global players competition landscape in this report is divided into three tiers. The first tiers is the global leading enterprise, which occupies a major market share, is in a leading position in the industry, has strong competitiveness and influence, and has a large revenue scale; the second tiers has a certain share and popularity in the market, actively follows the industry leaders in product, service or technological innovation, and has a medium revenue scale; the third tiers has a smaller share in the market, has a lower brand awareness, mainly focuses on the local market, and has a relatively small revenue scale.

This report studies the market size, price trends and future development prospects of Glucagon Like Peptide-1 (GLP-1) Agonists. Focus on analysing the market share, product portfolio, prices, sales volume, revenue and gross profit margin of global major manufacturers, as well as the market status and trends of different product types and applications in the global Glucagon Like Peptide-1 (GLP-1) Agonists market. The report data covers historical data from 2019 to 2023, based year in 2024 and forecast data from 2025 to 2030.

The regions and countries in the report include North America, Europe, China, APAC (excl. China), Latin America and Middle East and Africa, covering the Glucagon Like Peptide-1 (GLP-1) Agonists market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Glucagon Like Peptide-1 (GLP-1) Agonists industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.

The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.

Global Key Manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists Include:

Novo Nordisk

AstraZeneca

Eli Lily

GSK

Sanofi

Amylin

Bristol-Myers Squibb

Glucagon Like Peptide-1 (GLP-1) Agonists Product Segment Include:

Exenatied

Liraglutide

Lixisenatide

Albiglutide

Dulaglutide

Glucagon Like Peptide-1 (GLP-1) Agonists Product Application Include:

Hospital

Pharmacy

Other

Chapter Scope

Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trends

Chapter 2: Global Glucagon Like Peptide-1 (GLP-1) Agonists Industry PESTEL Analysis

Chapter 3: Global Glucagon Like Peptide-1 (GLP-1) Agonists Industry Porter's Five Forces Analysis

Chapter 4: Global Glucagon Like Peptide-1 (GLP-1) Agonists Major Regional Market Size (Revenue, Sales, Price) and Forecast Analysis

Chapter 5: Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Forecast by Type and Application Analysis

Chapter 6: North America Glucagon Like Peptide-1 (GLP-1) Agonists Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 7: Europe Glucagon Like Peptide-1 (GLP-1) Agonists Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 8: China Glucagon Like Peptide-1 (GLP-1) Agonists Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 9: APAC (Excl. China) Glucagon Like Peptide-1 (GLP-1) Agonists Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 10: Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 11: Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 12: Global Glucagon Like Peptide-1 (GLP-1) Agonists Competitive Analysis of Key Manufacturers (Sales, Revenue, Market Share, Price, Regional Distribution and Industry Concentration)

Chapter 13: Key Company Profiles (Product Portfolio, Sales, Revenue, Price and Gross Margin)

Chapter 14: Industrial Chain Analysis, Include Raw Material Suppliers, Distributors and Customers

Chapter 15: Research Findings and Conclusion

Chapter 16: Methodology and Data Sources

Table of Contents

1 Glucagon Like Peptide-1 (GLP-1) Agonists Market Overview

1.1 Product Definition and Statistical Scope

1.2 Glucagon Like Peptide-1 (GLP-1) Agonists Product by Type

1.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Type, 2023 VS 2024 VS 2030

1.2.2 Exenatied

1.2.3 Liraglutide

1.2.4 Lixisenatide

1.2.5 Albiglutide

1.2.6 Dulaglutide

1.3 Glucagon Like Peptide-1 (GLP-1) Agonists Product by Application

1.3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Application, 2023 VS 2024 VS 2030

1.3.2 Hospital

1.3.3 Pharmacy

1.3.4 Other

1.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Revenue and Sales Analysis

1.4.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Analysis (2019-2030)

1.4.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Sales Analysis (2019-2030)

1.4.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Sales Price Trend Analysis (2019-2030)

1.5 Glucagon Like Peptide-1 (GLP-1) Agonists Market Development Status and Trends

1.5.1 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Development Status Analysis

1.5.2 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Development Trends Analysis

2 Glucagon Like Peptide-1 (GLP-1) Agonists Market PESTEL Analysis

2.1 Political Factors Analysis

2.2 Economic Factors Analysis

2.3 Social Factors Analysis

2.4 Technological Factors Analysis

2.5 Environmental Factors Analysis

2.6 Legal Factors Analysis

3 Glucagon Like Peptide-1 (GLP-1) Agonists Market Porter's Five Forces Analysis

3.1 Competitive Rivalry

3.2 Threat of New Entrants

3.3 Bargaining Power of Suppliers

3.4 Bargaining Power of Buyers

3.5 Threat of Substitutes

4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Analysis by Regions

4.1 Glucagon Like Peptide-1 (GLP-1) Agonists Overall Market: 2023 VS 2024 VS 2030

4.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue and Forecast Analysis (2019-2030)

4.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue and Market Share by Region (2019-2024)

4.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Forecast by Region (2025-2030)

4.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Forecast Analysis (2019-2030)

4.3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Market Share by Region (2019-2024)

4.3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Region (2025-2030)

4.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Price Trend Analysis (2019-2030)

5 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Type and Application

5.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Type

5.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue and Forecast Analysis by Type (2019-2030)

5.1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Forecast Analysis by Type (2019-2030)

5.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Application

5.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue and Forecast Analysis by Application (2019-2030)

5.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Forecast Analysis by Application (2019-2030)

6 North America

6.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate Analysis (2019-2030)

6.2 North America Key Manufacturers Analysis

6.3 North America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Type

6.3.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2019-2030)

6.3.2 North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2019-2030)

6.4 North America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Application

6.4.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2019-2030)

6.4.2 North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2019-2030)

6.5 North America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country

6.5.1 US

6.5.2 Canada

7 Europe

7.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate Analysis (2019-2030)

7.2 Europe Key Manufacturers Analysis

7.3 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Type

7.3.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2019-2030)

7.3.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2019-2030)

7.4 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Application

7.4.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2019-2030)

7.4.2 ? Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2019-2030)

7.5 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country

7.5.1 Germany

7.5.2 France

7.5.3 United Kingdom

7.5.4 Italy

7.5.5 Spain

7.5.6 Benelux

8 China

8.1 China Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate Analysis (2019-2030)

8.2 China Key Manufacturers Analysis

8.3 China Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Type

8.3.1 China Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2019-2030)

8.3.2 China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2019-2030)

8.4 China Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Application

8.4.1 China Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2019-2030)

8.4.2 China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2019-2030)

9 APAC (excl. China)

9.1 APAC (excl. China) Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate Analysis (2019-2030)

9.2 APAC (excl. China) Key Manufacturers Analysis

9.3 APAC (excl. China) Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Type

9.3.1 APAC (excl. China) Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2019-2030)

9.3.2 APAC (excl. China) Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2019-2030)

9.4 APAC (excl. China) Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Application

9.4.1 APAC (excl. China) Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2019-2030)

9.4.2 APAC (excl. China) Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2019-2030)

9.5 APAC (excl. China) Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country

9.5.1 Japan

9.5.2 South Korea

9.5.3 India

9.5.4 Australia

9.5.5 Indonesia

9.5.6 Vietnam

9.5.7 Malaysia

9.5.8 Thailand

10 Latin America

10.1 Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate Analysis (2019-2030)

10.2 Latin America Key Manufacturers Analysis

10.3 Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Type

10.3.1 Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2019-2030)

10.3.2 Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2019-2030)

10.4 Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Application

10.4.1 Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2019-2030)

10.4.2 Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2019-2030)

10.5 Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country

10.5.1 Mexico

10.5.2 Brazil

11 Middle East & Africa

11.1 Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate Analysis (2019-2030)

11.2 Middle East & Africa Key Manufacturers Analysis

11.3 Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Type

11.3.1 Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2019-2030)

11.3.2 Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2019-2030)

11.4 Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Application

11.4.1 Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2019-2030)

11.4.2 Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2019-2030)

11.5 Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country

11.5.1 Saudi Arabia

11.5.2 South Africa

12 Competition by Manufacturers

12.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Sales, Revenue and Price by Key Manufacturers (2020-2024)

12.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Sales by Key Manufacturers (2020-2024)

12.1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Revenue by Key Manufacturers (2020-2024)

12.1.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Average Sales Price by Manufacturers (2020-2024)

12.2 Glucagon Like Peptide-1 (GLP-1) Agonists Competitive Landscape Analysis and Market Dynamic

12.2.1 Glucagon Like Peptide-1 (GLP-1) Agonists Competitive Landscape Analysis

12.2.2 Global Key Manufacturers Headquarter Location and Key Area Sales

12.2.3 Market Dynamic

13 Key Companies Analysis

13.1 Novo Nordisk

13.1.1 Novo Nordisk Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)

13.1.2 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio

13.1.3 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2020-2024)

13.2 AstraZeneca

13.2.1 AstraZeneca Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)

13.2.2 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio

13.2.3 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2020-2024)

13.3 Eli Lily

13.3.1 Eli Lily Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)

13.3.2 Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio

13.3.3 Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2020-2024)

13.4 GSK

13.4.1 GSK Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)

13.4.2 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio

13.4.3 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2020-2024)

13.5 Sanofi

13.5.1 Sanofi Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)

13.5.2 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio

13.5.3 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2020-2024)

13.6 Amylin

13.6.1 Amylin Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)

13.6.2 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio

13.6.3 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2020-2024)

13.7 Bristol-Myers Squibb

13.7.1 Bristol-Myers Squibb Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)

13.7.2 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio

13.7.3 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2020-2024)

14 Industry Chain Analysis

14.1 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Chain Analysis

14.2 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Upstream Supply Analysis

14.2.1 Upstream Key Raw Material Supply Analysis

14.2.2 Raw Material Suppliers and Contact Information

14.3 Glucagon Like Peptide-1 (GLP-1) Agonists Typical Downstream Customers

14.4 Glucagon Like Peptide-1 (GLP-1) Agonists Sales Channel Analysis

15 Research Findings and Conclusion

16 Methodology and Data Source

16.1 Methodology/Research Approach

16.2 Research Scope

16.3 Benchmarks and Assumptions

16.4 Date Source

16.4.1 Primary Sources

16.4.2 Secondary Sources

16.5 Data Cross Validation

16.6 Disclaimer

Name*

Email ID*

Company*

Phone (With Country Code)*

What is/are your question(s)?:

Publisher: DIResearch

Related Reports

Global Epilepsy Therapeutics Market (2024 Edition): Analysis By Generation (First Generation, Second Generation, Third Generation), By Route of Administration, By Type, By Region, By Country: Market Insights and Forecast (2020-2030)

Global Online Pharmacy Market (2024 Edition): Analysis By Drug Type (Over the Counter (OTC) Drugs, Prescription Drugs, Others), By Platform, By Product Type, By Region: Market Insights and Forecast (2020-2030)

Global Diagnostic X-rays Market (2024 Edition): Analysis By Type (General Radiography, Angiography, Surgical Fluoroscopy, Mobile X ray, Other Types), By End Users, By Region, By Country: Market Insights and Forecast (2020-2030)

Global Diagnostic Labs Market (2024 Edition): Analysis By Testing Services (Physiological Function Testing, General and Clinical Testing, Esoteric Testing, Specialized Testing, and Others), By Lab Type, By Application: Market Insights and Forecast (2020-2030)

Lateral Flow Assays Market By Product Type (Lateral Flow Readers {Digital/Mobile Readers and Benchtop Readers} and Kits and Reagents), By Application (Clinical Testing {Pregnancy Testing, Influenza Testing, Tuberculosis, D-Dimer Testing, and Other Clinical Testing}, Drug Abuse Testing, Veterinary Diagnostics, Food Safety & Environmental Testing, and Other Applications), By Technique (Sandwich Assay, Competitive Assay, and Multiplex Assay), By End-User (Home Care, Hospitals and Clinics, and Other End Users), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 - 2035

Why Market Study Report?

Best Price for Reports
Large Report Database
Easily Customize Reports
24/7 Email & Phone Support